Hematology market trends signal a competitive shift toward earlier-line treatment, as bispecific antibodies, BTK inhibitors, MRD-based evidence and evolving guidelines reshape treatment sequencing, clinical differentiation and commercial positioning across multiple myeloma, CLL and other hematologic diseases.
Coverage: 16 September – 22 October 2026
Introduction
The defining story in hematology during this reporting period was the advance of targeted therapies into earlier treatment lines, raising the competitive importance of treatment sequencing, clinical differentiation and practical adoption.
Regulatory developments in multiple myeloma and chronic lymphocytic leukemia (CLL) brought newer treatment approaches closer to broader patient populations. At the same time, emerging clinical evidence, revised treatment guidelines and regulatory execution challenges highlighted the factors that will determine how these therapies compete.
The central question is no longer simply which treatments demonstrate meaningful activity, but which can establish a durable place within increasingly complex treatment pathways.
Executive Summary
- Earlier-line expansion intensifies competition in multiple myeloma and CLL. European regulatory recommendations for teclistamab- and talquetamab-based regimens, alongside U.S. approval of first-line pirtobrutinib in selected CLL/SLL patients, signal growing competition for positions previously occupied by established treatment approaches. Clinical sequencing and patient selection will become more consequential.
- MRD negativity strengthens clinical differentiation, but safety and durability remain critical. Phase 3 results for iberdomide in relapsed multiple myeloma demonstrate the potential of targeted protein degradation to deliver deeper responses. However, confirmatory survival evidence and management of treatment-related toxicity will remain important for sustained adoption.
- Guideline integration and regulatory execution influence commercialization. Rusfertide’s NCCN Category 1 recommendation across polycythemia vera risk categories supports a treatment approach centered on phlebotomy burden. Meanwhile, denecimig’s delayed U.S. regulatory review illustrates how manufacturing readiness can affect market entry despite supportive clinical evidence.
- Novel hematology approaches seek to address remaining treatment limitations. Investigational CAR T-cell combinations and oral therapies targeting alternative biological pathways reflect continued interest in improving response durability and expanding therapeutic options. These programs remain early, making clinical validation and development execution important uncertainties.
Companies covered: Johnson & Johnson / Janssen, Eli Lilly, Bristol Myers Squibb, Takeda, Sanofi
Diseases covered: Multiple myeloma, Chronic lymphocytic leukemia, Polycythemia vera (PV), Hemophilia A, Sickle cell disease (SCD)
Watch the video summary
Strategic Perspective on Hematology Market Trends and Competitive Shifts
Earlier-Line Bispecific Antibodies and BTK Inhibitors Reshape Multiple Myeloma and CLL Treatment
Movement into earlier treatment lines was the clearest competitive development across hematologic malignancies during the reporting period.
In multiple myeloma, Johnson & Johnson received a positive European CHMP opinion for teclistamab monotherapy after at least one prior therapy. In the Phase 3 MajesTEC-9 study, teclistamab reduced the risk of progression or death by 71% and the risk of death by 40% compared with standard-of-care regimens.
A subsequent CHMP recommendation for talquetamab plus daratumumab further strengthens the prospect of earlier use of bispecific antibodies targeting different antigens.
These developments create opportunities for BCMA- and GPRC5D-directed therapies while introducing more complex questions about treatment sequencing, prior exposure and resistance.
A similar shift is emerging in CLL/SLL. The FDA approved non-covalent BTK inhibitor pirtobrutinib for previously untreated patients without known 17p deletion. The BRUIN CLL-313 study demonstrated significantly improved progression-free survival compared with bendamustine and rituximab.
However, that result does not establish superiority over contemporary targeted treatment options.
Market implication: Earlier-line positioning could substantially expand the commercial opportunity for advanced therapies, but competitive success will depend on demonstrating value within specific treatment sequences and patient populations.
Key uncertainty: How clinicians will position newer therapies against established targeted regimens, particularly where direct comparative evidence remains limited.
MRD Negativity Raises the Evidence Bar for Multiple Myeloma Treatment
Clinical differentiation in multiple myeloma is becoming more demanding as effective treatment options expand.
Bristol Myers Squibb’s Phase 3 EXCALIBER-RRMM study demonstrated an MRD-negative complete response rate of 41.1% with iberdomide, daratumumab and dexamethasone, compared with 20.7% for daratumumab, bortezomib and dexamethasone.
The results support the potential of cereblon E3 ligase modulators and targeted protein degradation as additional approaches in relapsed disease.
Iberdomide’s accelerated U.S. approval based on MRD-negative complete response also highlights the regulatory relevance of deeper response measures. However, progression-free survival remains a dual primary endpoint under evaluation in the confirmatory cohort.
Safety creates another dimension of differentiation. Grade 3/4 neutropenia occurred in 84.3% of patients receiving the iberdomide regimen, compared with 11.3% in the comparator group. Severe infections were also more frequent.
Teclistamab’s survival results similarly demonstrate meaningful efficacy alongside elevated infection risks.
These findings reinforce the importance of assessing efficacy and treatment burden together rather than viewing response depth as an isolated competitive advantage.
Market implication: Companies offering compelling efficacy with manageable toxicity, practical administration and sustainable supportive-care requirements may have an advantage across academic and community treatment settings.
Key uncertainty: Whether improvements in early response measures will translate into sufficiently durable clinical benefits to justify additional safety monitoring and treatment complexity.
Polycythemia Vera Treatment Guidelines and Hemophilia Regulation Shape Market Access
Treatment adoption depends not only on clinical evidence but also on guideline positioning, regulatory readiness and practical integration into care.
In polycythemia vera (PV), rusfertide received an NCCN Category 1 recommendation across low- and high-risk disease for patients with frequent phlebotomy requirements or intolerance.
The Phase 3 VERIFY study demonstrated that 76.9% of rusfertide-treated patients required no phlebotomies during the primary assessment period, compared with 32.9% receiving placebo.
The recommendation is significant because it addresses a defined management problem across conventional risk categories. Rusfertide does not universally replace cytoreductive therapy, particularly when broader disease manifestations require treatment.
Its commercial opportunity may therefore depend on identifying patients whose existing regimens fail to provide adequate hematocrit control or impose substantial treatment burden.
In hemophilia A, Novo Nordisk’s denecimig encountered a different challenge. Manufacturing-related deficiencies delayed the U.S. review despite the absence of identified clinical efficacy or safety deficiencies in the application. A positive European CHMP opinion illustrates how regulatory progress may diverge across geographic markets.
Market implication: Guideline recommendations can clarify the role of differentiated therapies, while manufacturing and regulatory execution can determine when those opportunities become commercially accessible.
Key uncertainty: How quickly guideline inclusion and regional regulatory progress translate into reimbursement decisions, prescribing patterns and sustained patient access.
CAR T-Cell Combinations and Novel Oral Therapies Expand Hematology Drug Development
While approved therapies move earlier in treatment, investigational programs are addressing limitations that remain unresolved by existing approaches.
In ultra-high-risk multiple myeloma, an NCI-funded development program will investigate RedHill Biopharma’s opaganib in combination with CAR T-cell therapy.
The approach aims to evaluate whether inhibition of sphingosine kinase-2 can improve cellular therapy activity and potentially extend treatment responses. The underlying rationale is supported by preclinical findings, but clinical benefit remains unproven.
This illustrates a possible direction for cellular therapy development: enhancing the effectiveness and durability of established modalities rather than relying exclusively on new cell therapy platforms.
Elsewhere, FDA orphan drug designation for vTv Therapeutics’ investigational oral Nrf2/Bach1 modulator HPPD in sickle cell disease reflects continued exploration of alternative therapeutic mechanisms.
The designation offers a development incentive, not evidence of clinical effectiveness.
These programs represent distinct opportunities within hematology, but both remain dependent on translating biological rationale into demonstrable patient benefit.
Market implication: Mechanistically differentiated approaches may create opportunities for smaller developers and strategic partners, particularly where existing therapies leave substantial unmet needs.
Key uncertainty: Whether early-stage programs can establish meaningful efficacy, acceptable safety and practical treatment delivery sufficient to support further development and commercialization.
What to Watch Next in the Hematology Treatment Landscape
- Earlier-line multiple myeloma competition: Final European regulatory decisions and implementation of expanded teclistamab and talquetamab indications will help establish how bispecific antibodies enter earlier treatment pathways.
- Iberdomide confirmatory evidence: Progression-free survival findings from EXCALIBER-RRMM will be central to assessing durability and supporting continued regulatory approval.
- First-line CLL treatment positioning: Pirtobrutinib’s adoption relative to established targeted therapies will clarify its clinical and commercial role beyond comparisons with chemoimmunotherapy.
- PV guideline adoption and hemophilia access: Rusfertide prescribing across risk categories and resolution of denecimig’s manufacturing-related regulatory issues will provide evidence of commercial execution.
- Emerging treatment combinations: Early clinical findings from opaganib plus CAR T-cell therapy will help determine whether combination strategies can improve outcomes in ultra-high-risk myeloma.
Key Takeaway: Treatment Sequencing and Clinical Value Drive Hematology Competition
- The hematology market is entering a more competitive phase in which earlier-line access alone will not guarantee commercial differentiation.
- The reporting period demonstrates how advanced therapies are moving toward broader patient populations while facing increasingly demanding expectations around survival benefit, response durability, safety and practical use.
- At the same time, guideline integration, manufacturing readiness and regional regulatory progress remain essential to translating clinical advances into patient access.
- For biopharma companies and investors, the principal strategic implication is clear: sustainable competitive advantage will depend on demonstrating not only that a therapy works, but where it offers the strongest clinical value within an evolving treatment pathway.
🌐 Explore LucidQuest Strategic Roundups across multiple therapy areas for deeper healthcare and pharma analysis
About LucidQuest
LucidQuest helps organizations anticipate change by identifying emerging signals, market shifts, and strategic opportunities.
Learn more: www.lqventures.com
Contact us at: info@lqventures.com